Novavax, Inc. (NVAX) — closed signal from March 8, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 6, 2026.
Predicted vs. what happened
What happened
Reached 74% of the predicted growth at its peak, without hitting the target.
The thesis — published March 8, 2026
Novavax's outlook improved in ways investors can value now: the company surprised with a profitable quarter, its licensing and royalty income is rising, and new terms with Pfizer and Sanofi add clearer near-term cash potential beyond seasonal vaccine sales. The stock can still swing sharply, but the current setup supports a possible rebound in the next 0-3 months.
Primary drivers
- Profitability surprise made investors more confident
- Licensing and royalties add steady income sources
- Deals with Pfizer and Sanofi boost near-term cash flow
- Company operating story is improving, supporting a rebound
How it played out
NVAX: rebound helped, but the target was not reached
Lyra published NVAX at $9.98 on March 8, 2026, with 22% expected growth and a $12.18 target. The thesis pointed to a profitable quarter, rising licensing and royalty income, Pfizer and Sanofi terms, and an improving operating story that could support a rebound within 0-3 months.
Inside the window, the stock did rebound, but not enough. It peaked at $11.61 on May 27, 2026, for a 16.3% gain, and stayed below the target. It ended at $9.49 on June 6, 2026. The thesis partially played out.
What happened during the window
On May 6, 2026, Novavax reported first-quarter 2026 results and operational highlights, including total revenue of $140 million. The same release said Novavax had signed new material transfer agreements in April and reiterated its 2026 revenue framework.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.